All data are based on the daily closing price as of February 18, 2026
h
Hanmi Pharm. Co.
128940.KO
416.14 USD
-11.41
-2.67%
Overview
Last close
416.14 usd
Market cap
5.28B usd
52 week high
431.89 usd
52 week low
146.58 usd
Target price
380.25 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
5.1977
Price/Book Value
6.436
Enterprise Value
5.42B usd
EV/Revenue
5.3412
EV/EBITDA
28.603
Key financials
Revenue TTM
1.01B usd
Gross Profit TTM
560.11M usd
EBITDA TTM
203.40M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
1.46B usd
Net debt
243.70M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.